Strong 2024 performance and a positive outlook for 2025
London, 26 February 2025 – Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2024.
Riad Mishlawi, Chief Executive Officer of Hikma, said:
“It’s been another strong year for Hikma with double digit revenue growth, increased profits and a resilient margin. We continued to invest in the business to support our future progress, with a strategic acquisition alongside new partnerships and agreements. This momentum combined with our diversified portfolio, leading market positions and increasing investment in R&D, underpin our positive outlook for 2025 and confidence in the future.”
Reported results (statutory) | 2024 $ million | 2023 $ million | Change | Constant currency[1] change |
Revenue | 3,127 | 2,875 | 9% | 9% |
Operating profit | 612 | 367 | 67% | 71% |
Profit attributable to shareholders | 359 | 190 | 89% | 98% |
Cashflow from operating activities | 564 | 608 | (7)% | - |
Basic earnings per share (cents) | 162 | 86 | 88% | 98% |
Total dividend per share (cents) | 80 | 72 | 11% | - |
Core results[2] (underlying) | 2024 $ million | 2023 $ million | Change | Constant currency1 change |
Core revenue | 3,156 | 2,875 | 10% | 10% |
Core operating profit | 719 | 707 | 2% | 4% |
Core EBITDA2 | 824 | 810 | 2% | 4% |
Core profit attributable to shareholders | 495 | 492 | 1% | 5% |
Core basic earnings per share (cents) | 224 | 223 | 0% | 4% |
[1] Constant currency numbers in 2024 represent reported 2024 numbers translated using 2023 exchange rates, excluding price increases in the business resulting from the devaluation of currencies
[2] Core results throughout the document are presented to show the underlying performance of the Group, excluding exceptional items and other adjustments set out in Note 5 of this release. Core results are a non-IFRS measure. See page 14 for a reconciliation to reported IFRS results